Penn Medicine is conducting medical studies to develop new diagnostic and clinical treatments to improve current standards of care.
Recently Added/Updated trials
Effects of Phloroglucinol vs. Placebo on IBS-D (Irritable Bowel Syndrome- Predominant Diarrhea)
Phase 2
To evaluate the clinical response of multiple dose strengths of CIN-103 relative to placebo on abdominal pain and stool consistency (as a composite responder) in subjects with IBS-D (Irritable Bowel Syndrome Prominently Diarrhea) over 12 weeks of treatment and the safety and tolerability of multiple dose strengths of CIN-103 relative to placebo in subjects with IBS-D over 12 weeks of treatment. The population is adult subjects 18 years and older who meet Rome IV Criteria for IBS-D and do not have evidence of other gastrointestinal diseases.
IPS TMS for Patients with PTSD
Phase 1
This study will be the first of its kind to explore the impact of continuous theta burst stimulation (cTBS) to the intraparietal sulcus (IPS) on arousal symptoms among patients with posttraumatic stress disorder (PTSD). We will demonstrate that IPS cTBS results in significant target engagement in the form of reduction in anxiety-potentiated startle (APS) compared to sham cTBS and will identify the ideal dose of cTBS.
HPTN102/ Purpose 3 LEN in Women
This is a Phase 2, open-label, multicenter, randomized study to evaluate the
PK, safety, and acceptability of LEN subcutaneous (SC) injection compared with oral F/TDF in cisgender women who would benefit from PrEP. This study has 2 parts. Randomized Phase: ppts will be randomized in a 1:1 ratio to receive 52 wks of LEN or F/TDF, followed by up to 78 wks of F/TDF for both study drug groups in the PK Tail Phase. Participants in the LEN group will transition to F/TDF for the PK Tail Phase.
Integrating Brain, Neurocognitive, and Computational Tools in Opioid Use Disorder (OUD) to Characterize Executive Function and to Predict Clinical Outcomes
Phase 3
The 5-year K01 Mentored Research Scientist proposal will
employ brain, neurocognitive, and computational tools (e.g., machine learning)
to understand the impact of opioid-use disorder (OUD) and common co-occurring
issues on executive function and clinical outcomes.
Opioid and Brain Study
Have problem with opiates? You may qualify for the study if you are: - Between 18–60 years old - In treatment or seeking treatment for opioid use problems - Willing to complete one MRI scan of the brain The study will investigate the psychological and brain mechanisms of opioid use disorder. There will be a screening visit that includes a urine drug test, physical exam, questionnaires and interviews. Eligible participants will undergo a brain MRI session, followed by 6 visits over 25 weeks. The study also includes optional phone/text surveys. MRI uses magnetic fields to take pictures of the brain – it does not use X-rays and is non-invasive. All participants will be compensated for their participation. This study does not provide treatment.
CureTalks@Penn interviews Penn Medicine physicians about their cutting edge research and clinical trials. Our goal is to inform patients, care-givers, patient advocates and other physicians about research that occurs at Penn Medicine.
